Hikma Sees FY10 In Line With Views; Says Gross Margins Higher Than 09
November 12 2010 - 2:55AM
Dow Jones News
Hikma Pharmaceuticals PLC (HIK.LN), a multinational
pharmaceutical group, Friday reiterated its guidance for full year
group revenue growth in the low teens and said gross margins would
be higher than in 2009.
MAIN FACTS:
-Confirms guidance of low double digit revenue growth for the
Branded business for the full year.
-Sales in global injectables business have been accelerating in
the second half.
-Continues to expect to deliver at least 20% sales growth in
generics business for the full year with a high operating
margin.
-Financing position remains strong, allowing the company to
actively pursue acquisition opportunities across the business.
-Remains confident that strategy of organic growth supplemented
by acquisitions and partnerships will continue to deliver excellent
results for the Group.
-Shares at closed Thursday at 783 pence valuing the company at
GBP1.51 billion.
-By Peter Evans, Dow Jones Newswires; 44-20-7842-9308;
peter.evans@dowjones.com
Hikma Pharmaceuticals (PK) (USOTC:HKMPY)
Historical Stock Chart
From Sep 2024 to Oct 2024
Hikma Pharmaceuticals (PK) (USOTC:HKMPY)
Historical Stock Chart
From Oct 2023 to Oct 2024